Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: Implications for specific immunotherapy

Vaccine

Volumn 28, Issue 31, 2010, Pages 5075-5085

  Broos, Sissela ^a   Lundberg, Kristina ^a   Akagi, Takami ^b   Kadowaki, Koji ^b   Akashi, Mitsuru ^b   Greiff, Lennart ^c   Borrebaeck, Carl A K ^a   Lindstedt, Malin ^a  

^a LUND UNIVERSITY   (Sweden)

^b OSAKA UNIVERSITY   (Japan)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allergy; Antigen presentation; Vaccination

Indexed keywords

ALLERGEN; CHEMOKINE; GRASS POLLEN EXTRACT; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INTERLEUKIN 10; NANOPARTICLE; POLY(GAMMA GLUTAMIC ACID); POLYGLUTAMIC ACID; UNCLASSIFIED DRUG; IL10 PROTEIN, HUMAN; POLY(GAMMA-GLUTAMIC ACID); TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; PHLEUM PRATENSE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANTIGEN PRESENTATION; CELL PROLIFERATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; POACEAE; POLLEN;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKIN-10; NANOPARTICLES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POACEAE; POLLEN; POLYGLUTAMIC ACID; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 77954760985     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.004     Document Type: Article

References (56)

1. D'Amato G., Spieksma F.T., Liccardi G., Jager S., Russo M., Kontou-Fili K., et al. Pollen-related allergy in Europe. Allergy 1998, 53(6):567-578.
2. Vrtala S., Sperr W.R., Reimitzer I., van Ree R., Laffer S., Muller W.D., et al. cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Phl pV allergen. J Immunol 1993, 151(9):4773-4781.
3. Akdis M., Akdis C.A. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Imm 2007, 119(4):780-791.
4. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106(3):263-266.
5. Jarnicki A.G., Tsuji T., Thomas W.R. Inhibition of mucosal and systemic T(h)2-type immune responses by intranasal peptides containing a dominant T cell epitope of the allergen Der p 1. Int immunol 2001, 13(10):1223-1231.
6. Tsitoura D.C., DeKruyff R.H., Lamb J.R., Umetsu D.T. Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J Immunol 1999, 163(5):2592-2600.
7. Wiedermann U., Herz U., Baier K., Vrtala S., Neuhaus-Steinmetz U., Bohle B., et al. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice. Int Arch Allergy Imm 2001, 126(1):68-77.
8. Winkler B., Baier K., Wagner S., Repa A., Eichler H.G., Scheiner O., et al. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy 2002, 32(1):30-36.
9. Balenga N.A., Zahedifard F., Weiss R., Sarbolouki M.N., Thalhamer J., Rafati S. Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. J Biotechnol 2006, 124(3):602-614.
10. Scholl I., Weissenbock A., Forster-Waldl E., Untersmayr E., Walter F., Willheim M., et al. Allergen-loaded biodegradable poly(D,L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model. Clin Exp Allergy 2004, 34(2):315-321.
11. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 2007, 178(5):2979-2986.
12. Akagi T., Wang X., Uto T., Baba M., Akashi M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 2007, 28(23):3427-3436.
13. Wang X., Uto T., Akagi T., Akashi M., Baba M. Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine. J Med Virol 2008, 80(1):11-19.
14. Akagi T., Kaneko T., Kida T., Akashi M. Preparation and characterization of biodegradable nanoparticles based on poly(gamma-glutamic acid) with l-phenylalanine as a protein carrier. J Control Release 2005, 108(2-3):226-236.
15. Akagi T., Kaneko T., Kida T., Akashi M. Multifunctional conjugation of proteins on/into bio-nanoparticles prepared by amphiphilic poly(gamma-glutamic acid). J Biomater Sci Polym Ed 2006, 17(8):875-892.
16. Ahlstrom-Emanuelsson C., Persson C.G., Svensson C., Andersson M., Hosszu Z., Akerlund A., et al. Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid. Ann Allergy Asthma Immunol 2002, 89(2):159-165.
17. Lundberg K., Lindstedt M., Larsson K., Dexlin L., Wingren C., Ohlin M., et al. Augmented Phl p 5-specific Th2 response after exposure of dendritic cells to allergen in complex with specific IgE compared to IgG1 and IgG4. Clin Immunol 2008, 128(3):358-365.
18. Lindstedt M., Johansson-Lindbom B., Borrebaeck C.A. Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators. Int Immunol 2002, 14(10):1203-1213.
19. Lindstedt M., Schiott A., Bengtsson A., Larsson K., Korsgren M., Greiff L., et al. Genomic and functional delineation of dendritic cells and memory T cells derived from grass pollen-allergic patients and healthy individuals. Int immunol 2005, 17(4):401-409.
20. Huang Q., Liu D., Majewski P., Schulte L.C., Korn J.M., Young R.A., et al. The plasticity of dendritic cell responses to pathogens and their components. Science (New York, NY) 2001, 294(5543):870-875.
21. Sallusto F., Lanzavecchia A., Mackay C.R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998, 19(December (12)):568-574.
22. Frucht D.M. IL-23: a cytokine that acts on memory T cells. Sci STKE 2002, 2002(114):PE1.
23. Forster R., Schubel A., Breitfeld D., Kremmer E., Renner-Muller I., Wolf E., et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99(1):23-33.
24. Kabashima K., Shiraishi N., Sugita K., Mori T., Onoue A., Kobayashi M., et al. CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am J Pathol 2007, 171(4):1249-1257.
25. Yen J.H., Khayrullina T., Ganea D. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 2008, 111(1):260-270.
26. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27(1):111-122.
27. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999, 5(12):1365-1369.
28. Kuipers H., Muskens F., Willart M., Hijdra D., van Assema F.B., Coyle A.J., et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol 2006, 36(9):2472-2482.
29. Suciu-Foca N., Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 2007, 248(1):59-67.
30. Haridas V., Shrivastava A., Su J., Yu G.L., Ni J., Liu D., et al. VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 1999, 18(47):6496-6504.
31. Pomerantz J.L., Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J 1999, 18(23):6694-6704.
32. Kawagoe T., Sato S., Matsushita K., Kato H., Matsui K., Kumagai Y., et al. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 2008, 9(6):684-691.
33. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132(3):344-362.
34. Boone D.L., Turer E.E., Lee E.G., Ahmad R.C., Wheeler M.T., Tsui C., et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004, 5(10):1052-1060.
35. Fotin-Mleczek M., Henkler F., Hausser A., Glauner H., Samel D., Graness A., et al. Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation. J Biol Chem 2004, 279(1):677-685.
36. Uto T., Akagi T., Hamasaki T., Akashi M., Baba M. Modulation of innate and adaptive immunity by biodegradable nanoparticles. Immunol Lett 2009, 125(1):46-52.
37. Goda S., Imai T., Yoshie O., Yoneda O., Inoue H., Nagano Y., et al. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol 2000, 164(8):4313-4320.
38. Lillard J.W., Boyaka P.N., Hedrick J.A., Zlotnik A., McGhee J.R. Lymphotactin acts as an innate mucosal adjuvant. J Immunol 1999, 162(4):1959-1965.
39. Nguyen K.D., Fohner A., Booker J.D., Dong C., Krensky A.M., Nadeau K.C. XCL1 enhances regulatory activities of CD4+ CD25(high) CD127(low/-) T cells in human allergic asthma. J Immunol 2008, 181(8):5386-5395.
40. Jarrossay D., Napolitani G., Colonna M., Sallusto F., Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001, 31(11):3388-3393.
41. Lee T.Y., Kim Y.H., Yoon S.W., Choi J.C., Yang J.M., Kim C.J., et al. Oral administration of poly-gamma-glutamate induces TLR4- and dendritic cell-dependent antitumor effect. Cancer Immunol Immunother 2009, 58(11):1783-1796.
42. Re F., Strominger J.L. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001, 276(40):37692-37699.
43. Re F., Strominger J.L. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol 2004, 173(12):7548-7555.
44. Kim S., Yang J.Y., Lee K., Oh K.H., Gi M., Kim J.M., et al. Bacillus subtilis-specific poly-gamma-glutamic acid regulates development pathways of naive CD4(+) T cells through antigen-presenting cell-dependent and -independent mechanisms. Int Immunol 2009, 21(8):977-990.
45. Hamasaki T., Uto T., Akagi T., Akashi M., Baba M. Modulation of gene expression related to toll-like receptor signaling in dendritic cells by poly(gamma-glutamic acid) nanoparticles. Clin Vaccine Immunol 2010.
46. Strachan D.P. Hay fever, hygiene, and household size. BMJ (Clin Res) 1989, 299(6710):1259-1260.
47. Lauener R.P., Birchler T., Adamski J., Braun-Fahrlander C., Bufe A., Herz U., et al. Expression of CD14 and Toll-like receptor 2 in farmers' and non-farmers' children. Lancet 2002, 360(9331):465-466.
48. Chisholm D., Libet L., Hayashi T., Horner A.A. Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J Allergy Clin Immunol 2004, 113(3):448-454.
49. Redecke V., Hacker H., Datta S.K., Fermin A., Pitha P.M., Broide D.H., et al. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 2004, 172(5):2739-2743.
50. Patel M., Xu D., Kewin P., Choo-Kang B., McSharry C., Thomson N.C., et al. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 2005, 174(12):7558-7563.
51. Velasco G., Campo M., Manrique O.J., Bellou A., He H., Arestides R.S., et al. Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am J Respir Cell Mol Biol 2005, 32(3):218-224.
52. Revets H., Pynaert G., Grooten J., De Baetselier P. Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol 2005, 174(2):1097-1103.
53. McCormack P.L., Wagstaff A.J. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs 2006, 66(7):931-938.
54. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004, 4(6):469-478.
55. Hunter R., Strickland F., Kezdy F. The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J Immunol 1981, 127(3):1244-1250.
56. Meiler F., Zumkehr J., Klunker S., Ruckert B., Akdis C.A., Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008, 205(12):2887-2898.